Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.

Proceedings of the National Academy of Sciences of the United States of America - 25 Apr 2006

Williams Richard T, Roussel Martine F, Sherr Charles J

Abstract excerpt

Mouse bone marrow cells transduced with retroviral vectors encoding either of two oncogenic Bcr-Abl isoforms (p210(Bcr-Abl) and p185(Bcr-Abl)) induce B cell lympholeukemias when transplanted into lethally irradiated mice. If the activity of the Arf tumor suppressor is compromised, these donor cells initiate a much more highly aggressive and rapidly fatal disease. When mouse bone marrow cells expressing Bcr-Abl...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Genes, abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Interleukin-7

Share to Leukemia, Lymphoid

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Neoplasm Transplantation

Share to Tumor Suppressor Protein p14ARF

Source

Open in PubMed Open full text

Identifiers

PMID: 16618932
DOI: 10.1073/pnas.0602030103
PMCID: PMC1440588

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.PMID 16618932Read ↗

Loss of the BCR-FGFR1 GEF Domain Suppresses RHOA Activation and Enhances B-Lymphomagenesis in MiceSemantic proximity Read ↗

The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.Semantic proximity Read ↗

IRF-4 functions as a tumor suppressor in early B-cell developmentSemantic proximity Read ↗

Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome–positive acute lymphoblastic leukemiaSemantic proximity Read ↗

Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistanceSemantic proximity Read ↗

INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.Semantic proximity Read ↗

Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia.Semantic proximity Read ↗

Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivoSemantic proximity Read ↗

Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.Semantic proximity Read ↗

Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.Semantic proximity Read ↗

Immature B-cell progenitors survive oncogenic stress and efficiently initiate Ph+ B-acute lymphoblastic leukemia.Semantic proximity Read ↗

Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.